跳至主要内容
临床试验/ACTRN12614000948695
ACTRN12614000948695招募中未知

Evaluating the effectiveness of signal peptides in diagnosing pneumonia and heart failure in patients who present with acute shortness of breath.

Christchurch Heart Institute. University of Otago0 个研究点目标入组 1,200 人开始时间: 2014年9月4日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
1,200

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Eligible patients who report shortness of breath not due to trauma as their primary complaint upon presentation to the ED.

排除标准

  • Patients under 18 years of age or unable to provide consent are excluded.
  • Patients with an acute ST-elevation myocardial infarction and patients on haemodialysis for renal failure are also excluded.

研究者

发起方
Christchurch Heart Institute. University of Otago

相似试验

已完成
不适用
A study on efficacy of functional peptide-containing drink
JPRN-UMIN000020962Suntory Global Innovation Center Ltd.200
招募中
Unknown
Evaluation of the efficacy of a peptide-derived absorbable haemostatic agent in the prevention of post-operative bleeding in artificial ulcers caused by colon and gastric submucosal dissection: a single-centre prospective observational study.Early stage colorectal cancer, Early stage gastric cancer
JPRN-UMIN000050488Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital300
尚未招募
Unknown
Evaluation of the efficacy of a peptide-derived absorbable haemostatic agent in the prevention of post-operative bleeding in artificial ulcers caused by colon and gastric submucosal dissection: a multi-centric prospective observational study.
JPRN-UMIN000053488Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital200
进行中(未招募)
1 期
Anti-tumoral vaccination of melanoma patients with peptides associated with GM-CT-01, a vegetal derived sugar that binds to and blocks galectin, a protein produced by tumor cells that inhibits immune cells.Metastatic melanomaMedDRA version: 14.0Level: LLTClassification code 10025651Term: Malignant melanoma excisionSystem Organ Class: 10042613 - Surgical and medical proceduresMedDRA version: 14.0Level: LLTClassification code 10027150Term: Melanoma malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10042550Term: Superficial spreading melanoma stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10029488Term: Nodular melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10025662Term: Malignant melanoma of skin of scalp and neckSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10040891Term: Skin melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10056768Term: Malignant melanoma of skin of lower limb, incl hipSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10048434Term: Melanoma malignant aggravatedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: LLTClassification code 10042548Term: Superficial spreading melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.0Level: PTClassification code 10025652Term: Malignant melanoma in situSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2010-018638-29-BECentre du Cancer des Cliniques Universitaires Saint-Luc6
进行中(未招募)
1 期
Phase I/II study of peptide vaccination associated with tumoral immunomodulation with proinflammatory cytokines and imiquimod in patients with advanced metastatic melanoma
EUCTR2010-020435-40-BECentre du Cancer3